A new meta-analysis has given fresh insights into the optimal sequence of first- and second-line therapies in moderate-to-severe Crohn’s disease, gastroenterologists say.
The systematic review and network meta-analysis included 31 clinical trials of TNF inhibitors (infliximab, adalimumab, and certolizumab pegol), anti-integrins (vedolizumab), anti-IL-12/23p40 agents (ustekinumab), and anti-IL-23p19 agents (risankizumab).